Aug 05, 2026 —
Galibra Neuroscience announced that the U.S. Food and Drug Administration has granted both Orphan Drug Designation and Rare Pediatric Disease Designation to its investigational AAV gene therapy for succinic semialdehyde dehydrogenase deficiency, or SSADH deficiency.
The dual designations support development of a potential first disease-modifying therapy for SSADH deficiency, an ultra-rare inherited neurometabolic disorder with no FDA-approved disease-modifying treatment.
SSADH deficiency is caused by pathogenic variants in the ALDH5A1 gene, which disrupt normal GABA metabolism and lead to accumulation of toxic neuroactive metabolites. The condition is associated with intellectual disability, autism spectrum disorder, epilepsy, and other neurologic and psychiatric manifestations.
Current treatment for SSADH deficiency is focused primarily on symptom management. Galibra’s program is being developed as an AAV-based gene replacement therapy intended to address the underlying genetic cause of the disease.
The program is supported by preclinical data generated at Boston Children’s Hospital and Harvard Medical School. Galibra said the therapy is on track to become the first gene replacement therapy specifically designed for SSADH deficiency.
Orphan Drug Designation is granted to drugs and biologics intended to treat rare diseases or conditions. The designation may provide development incentives including tax credits for qualified clinical testing, waiver of certain FDA application user fees, and potential seven-year orphan drug exclusivity if approved.
Rare Pediatric Disease Designation applies to products intended to treat serious or life-threatening rare diseases that primarily affect children. If Galibra’s therapy is ultimately approved and meets applicable requirements, the company may be eligible to receive a Rare Pediatric Disease Priority Review Voucher.
Galibra is currently advancing IND-enabling activities for its SSADH deficiency program and is working with academic and patient advocacy partners toward initiation of clinical trials.
The program has been developed in close collaboration with the SSADH Association and the broader international patient community. The organization has supported natural history research, patient engagement, and therapeutic development for the disorder.
Aurelix Bio is providing strategic clinical development, regulatory planning, translational medicine, and operational support to help advance the program toward first-in-human studies.
The designations mark an important regulatory step for Galibra’s AAV gene therapy program and reinforce the broader push to develop disease-modifying genetic medicines for ultra-rare pediatric neurologic disorders.
